Cite
HARVARD Citation
Kavanaugh, A. et al. (n.d.). FRI0447 Long-Term (156-Week) Efficacy and Safety Profile of Apremilast, An Oral Phosphodiesterase 4 Inhibitor, in Patients with Psoriatic Arthritis: Results from A Phase III, Randomized, Controlled Trial and Open-Label Extension (Palace 1). Annals of the rheumatic diseases. pp. 597-598. [Online].